597 related articles for article (PubMed ID: 23668917)
1. Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS).
Binda D; Vanhoutte EK; Cavaletti G; Cornblath DR; Postma TJ; Frigeni B; Alberti P; Bruna J; Velasco R; Argyriou AA; Kalofonos HP; Psimaras D; Ricard D; Pace A; Galiè E; Briani C; Dalla Torre C; Lalisang RI; Boogerd W; Brandsma D; Koeppen S; Hense J; Storey D; Kerrigan S; Schenone A; Fabbri S; Rossi E; Valsecchi MG; Faber CG; Merkies IS; ; Galimberti S; Lanzani F; Mattavelli L; Piatti ML; Bidoli P; Cazzaniga M; Cortinovis D; Lucchetta M; Campagnolo M; Bakkers M; Brouwer B; Boogerd W; Grant R; Reni L; Piras B; Pessino A; Padua L; Granata G; Leandri M; Ghignotti I; Plasmati R; Pastorelli F; Heimans JJ; Eurelings M; Meijer RJ; Grisold W; Lindeck Pozza E; Mazzeo A; Toscano A; Russo M; Tomasello C; Altavilla G; Penas Prado M; Dominguez Gonzalez C; Dorsey SG
Eur J Cancer; 2013 Sep; 49(13):2910-8. PubMed ID: 23668917
[TBL] [Abstract][Full Text] [Related]
2. Improving assessment in small fiber neuropathy.
Brouwer BA; Bakkers M; Hoeijmakers JG; Faber CG; Merkies IS
J Peripher Nerv Syst; 2015 Sep; 20(3):333-40. PubMed ID: 26114213
[TBL] [Abstract][Full Text] [Related]
3. The Val30Met familial amyloid polyneuropathy specific Rasch-built overall disability scale (FAP-RODS(©) ).
Pruppers MH; Merkies IS; Faber CG; Da Silva AM; Costa V; Coelho T
J Peripher Nerv Syst; 2015 Sep; 20(3):319-27. PubMed ID: 26115039
[TBL] [Abstract][Full Text] [Related]
4. Rasch-Transformed Total Neuropathy Score clinical version (RT-TNSc(©) ) in patients with chemotherapy-induced peripheral neuropathy.
Binda D; Cavaletti G; Cornblath DR; Merkies IS;
J Peripher Nerv Syst; 2015 Sep; 20(3):328-32. PubMed ID: 26306547
[TBL] [Abstract][Full Text] [Related]
5. Development and psychometric evaluation of the chemotherapy-induced peripheral neuropathy assessment tool.
Tofthagen CS; McMillan SC; Kip KE
Cancer Nurs; 2011; 34(4):E10-20. PubMed ID: 21242773
[TBL] [Abstract][Full Text] [Related]
6. The Rasch-built Pompe-specific activity (R-PAct) scale.
van der Beek NA; Hagemans ML; van der Ploeg AT; van Doorn PA; Merkies IS
Neuromuscul Disord; 2013 Mar; 23(3):256-64. PubMed ID: 23273871
[TBL] [Abstract][Full Text] [Related]
7. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale.
Cavaletti G; Frigeni B; Lanzani F; Piatti M; Rota S; Briani C; Zara G; Plasmati R; Pastorelli F; Caraceni A; Pace A; Manicone M; Lissoni A; Colombo N; Bianchi G; Zanna C;
J Peripher Nerv Syst; 2007 Sep; 12(3):210-5. PubMed ID: 17868248
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools.
Cavaletti G; Frigeni B; Lanzani F; Mattavelli L; Susani E; Alberti P; Cortinovis D; Bidoli P
Eur J Cancer; 2010 Feb; 46(3):479-94. PubMed ID: 20045310
[TBL] [Abstract][Full Text] [Related]
9. Rasch model-based testing of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20) using Alliance for Clinical Trials in Oncology (Alliance) A151408 study data.
Smith EML; Zanville N; Kanzawa-Lee G; Donohoe C; Bridges C; Loprinzi C; Le-Rademacher J; Yang JJ
Support Care Cancer; 2019 Jul; 27(7):2599-2608. PubMed ID: 30460399
[TBL] [Abstract][Full Text] [Related]
10. The reliability and validity of a modified total neuropathy score-reduced and neuropathic pain severity items when used to measure chemotherapy-induced peripheral neuropathy in patients receiving taxanes and platinums.
Smith EM; Cohen JA; Pett MA; Beck SL
Cancer Nurs; 2010; 33(3):173-83. PubMed ID: 20357656
[TBL] [Abstract][Full Text] [Related]
11. Background noise: the experience of chemotherapy-induced peripheral neuropathy.
Bakitas MA
Nurs Res; 2007; 56(5):323-31. PubMed ID: 17846553
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice.
Beijers AJ; Vreugdenhil G; Oerlemans S; Eurelings M; Minnema MC; Eeltink CM; van de Poll-Franse LV; Mols F
Support Care Cancer; 2016 Jun; 24(6):2411-20. PubMed ID: 26634561
[TBL] [Abstract][Full Text] [Related]
13. A questionnaire survey of physicians' perspectives regarding the assessment of chemotherapy-induced peripheral neuropathy in patients with breast cancer.
Kuroi K; Shimozuma K; Ohashi Y; Takeuchi A; Aranishi T; Morita S; Ohsumi S; Watanabe T; Bain S; Hausheer FH
Jpn J Clin Oncol; 2008 Nov; 38(11):748-54. PubMed ID: 18845520
[TBL] [Abstract][Full Text] [Related]
14. Rasch-built Overall Disability Scale for Multifocal motor neuropathy (MMN-RODS(©) ).
Vanhoutte EK; Faber CG; van Nes SI; Cats EA; Van der Pol WL; Gorson KC; van Doorn PA; Cornblath DR; van den Berg LH; Merkies IS;
J Peripher Nerv Syst; 2015 Sep; 20(3):296-305. PubMed ID: 26329270
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale.
Frigeni B; Piatti M; Lanzani F; Alberti P; Villa P; Zanna C; Ceracchi M; Ildebrando M; Cavaletti G
J Peripher Nerv Syst; 2011 Sep; 16(3):228-36. PubMed ID: 22003937
[TBL] [Abstract][Full Text] [Related]
16. A prospective surveillance model for physical rehabilitation of women with breast cancer: chemotherapy-induced peripheral neuropathy.
Stubblefield MD; McNeely ML; Alfano CM; Mayer DK
Cancer; 2012 Apr; 118(8 Suppl):2250-60. PubMed ID: 22488699
[TBL] [Abstract][Full Text] [Related]
17. Internal construct validity of the Oxford Knee Scale: evidence from Rasch measurement.
Conaghan PG; Emerton M; Tennant A
Arthritis Rheum; 2007 Dec; 57(8):1363-7. PubMed ID: 18050174
[TBL] [Abstract][Full Text] [Related]
18. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20.
Postma TJ; Aaronson NK; Heimans JJ; Muller MJ; Hildebrand JG; Delattre JY; Hoang-Xuan K; Lantéri-Minet M; Grant R; Huddart R; Moynihan C; Maher J; Lucey R;
Eur J Cancer; 2005 May; 41(8):1135-9. PubMed ID: 15911236
[TBL] [Abstract][Full Text] [Related]
19. Improving fatigue assessment in immune-mediated neuropathies: the modified Rasch-built fatigue severity scale.
van Nes SI; Vanhoutte EK; Faber CG; Garssen M; van Doorn PA; Merkies IS;
J Peripher Nerv Syst; 2009 Dec; 14(4):268-78. PubMed ID: 20021568
[TBL] [Abstract][Full Text] [Related]
20. Rasch-built myotonic dystrophy type 1 activity and participation scale (DM1-Activ).
Hermans MC; Faber CG; De Baets MH; de Die-Smulders CE; Merkies IS
Neuromuscul Disord; 2010 May; 20(5):310-8. PubMed ID: 20363134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
